Cellzome is a world leader in chemoproteomics, transforming the sciences of epigenetics and signal transduction into novel drug candidates in inflammatory diseases and oncology.
Drug Discovery and Technology
Cellzome's technologies work with native proteins in a true physiological setting to discover small molecule drugs targeting protein complexes that underlie diseases and include:
Kinobeads™ technology works in physiological settings to direct the design of potent and selective small molecule drug candidates.
Episphere™ comprises a suite of quantitative proteomics technologies for the discovery of drug candidates for epigenetic targets
Partnering and Collaborations
Cellzome maintains the highest levels of scientific expertise and has several active collaborations with leading academic laboratories globally.
The Company has a track record in delivering significant collaborations with top pharmaceutical companies including GlaxoSmithKline, Johnson & Johnson and Novartis. If you are interested in discussing collaborative or partnering opportunities contact business@cellzome.com